PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Medical Science, BioPharmaceuticals, R&D, AstraZeneca, Tokyo, Japan. Electronic address: michiko.asano@astrazeneca.com.\', \'Medical Science, BioPharmaceuticals, R&D, AstraZeneca, Osaka, Japan.\', \'Science and Data Analytics, Oncology R&D, AstraZeneca, Osaka, Japan.\', \'Clinical Science, BioPharmaceuticals, R&D, AstraZeneca, Osaka, Japan.\', \'Science and Data Analytics, R&D, AstraZeneca, Osaka, Japan.\', \'Biopharma Clinical Operations, Development Operations, BioPharmaceuticals R&D, AstraZeneca, Tokyo, Japan.\', \'Microbial Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.\', \'Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.\', \'Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.\']
?:citedBy
  • -1
?:creator
?:doi
  • S1201-9712(21)00818-310.1016/j.ijid.2021.10.030
?:doi
?:hasPublicationType
?:journal
  • International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
is ?:pmid of
?:pmid
?:pmid
  • 34688944
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1/2 trial.
?:type
?:year
  • 2022

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/34688944>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/34688944>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all